Avalon Pharmaceuticals to Present at Susquehanna Financial Group Emerging Trends Conference 2006
30 October 2006 - 10:30PM
PR Newswire (US)
GERMANTOWN, Md., Oct. 30 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. (NASDAQ:AVRX)(NYSE:AVRX), a biopharmaceutical
company focused on the discovery and development of small molecule
therapeutics, today announced that Kenneth C. Carter, Ph.D.,
President and CEO, is scheduled to provide an update on the Company
at the 2006 Susquehanna Financial Group Emerging Trends Conference.
The meeting will be held at the Peninsula Hotel in New York City on
November 1, 2006. Dr. Carter is scheduled to present on Wednesday,
November 1st at 1:30 p.m., EST, in the Greenwich Room. A live audio
webcast of this presentation can be accessed on Avalon
Pharmaceuticals' website, http://www.avalonrx.com/ and a replay of
the presentation will be available for 90 days following the
conference. About Avalon Pharmaceuticals Avalon Pharmaceuticals is
a biopharmaceutical company focused on the discovery and
development of small molecule therapeutics through the use of a
comprehensive, innovative and proprietary suite of technologies
based upon large-scale gene expression analysis which it calls
AvalonRx(R). This platform facilitates drug discovery by expanding
the range of therapeutic targets for drug intervention, including
targets and target pathways frequently considered intractable using
conventional HTS approaches, allows more informed decisions about
which compounds to advance towards clinical trials, and facilitates
drug development through identification of biomarkers of efficacy
that can stratify patients or provide early indicators of response.
Avalon's focus is oncology but the company has discovery programs
in other therapeutic areas with partners. Avalon Pharmaceuticals
was established in 1999 and is headquartered in Germantown,
Maryland. Contacts: Avalon Pharmaceuticals, Inc. Noonan Russo Gary
Lessing Wendy Lau (Media) Executive Vice President & CFO Tel:
(212) 845-4272 Tel: (301) 556-9900 Fax: (301) 556-9910 The Trout
Group LLC Email: Chad Rubin (Investors) Tel: (212) 477-9007 ext. 47
DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: Gary Lessing,
Executive Vice President & CFO of Avalon Pharmaceuticals, Inc.,
+1-301-556-9900, fax: +1-301-556-9910, ; or Media: Wendy Lau of
Noonan Russo, +1-212-845-4272, for Avalon Pharmaceuticals, Inc.; or
Investors: Chad Rubin of The Trout Group LLC, +1-212-477-9007, ext.
47, for Avalon Pharmaceuticals, Inc. Web site:
http://www.avalonrx.com/
Copyright
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Avalon Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Avalon Pharmaceuticals (MM) News Articles